Novel Disease-Modifying Drugs against Skin Fibrosis of Systemic Sclerosis

Systemic sclerosis (SSc) or scleroderma is an autoimmune disorder characterized by tissue fibrosis of the skin and internal organs. The etiology of the skin fibrosis is thought to be thickened dermis due to uncontrolled excessive deposition of various extracellular matrix, mainly type I collagen.Systemic treatments with anti-inflammatory and cytotoxic immunosuppressive properties, such as corticosteroids and immunosuppressants, are usually considered for skin sclerosis of patients with SSc. However, their approach must be initiated at the early stage, before the fibrosis is completed, and the effects of the corticosteroids and immunosuppressants are known to be reduced in the late stages of the sclerosis. Furthermore, various significant adverse effects of these treatments must be considered.This paper discusses the present day understanding of therapeutic options using disease-modifying drugs against skin sclerosis of SSc patients and the possible mechanisms. 

• Publication year

  2019

• Venue

  Trends in Immunotherapy

• Publication date

  2019-02-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.24294/TI.V4.I2.1050
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic criteria, severity classification and guidelines of systemic sclerosis

  2018cited by this paper
• RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.

  2017cited by this paper
• Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

  2017cited by this paper
• Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

  2016cited by this paper
• B cell abnormalities and therapeutic strategies in systemic sclerosis.

  2016cited by this paper
• Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.

  2016cited by this paper
• Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.

  2015cited by this paper
• Cytokines in the immunopathology of systemic sclerosis

  2015cited by this paper
• Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis

  2014cited by this paper
• Targeted immunotherapies in systemic sclerosis.

  2014cited by this paper
• Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

  2014cited by this paper
• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

  2014cited by this paper
• Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

  2014cited by this paper
• Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients.

  2013cited by this paper
• Imatinib mesylate in scleroderma‐associated diffuse skin fibrosis: a phase II multicentre randomized double‐blinded controlled trial

  2012cited by this paper
• Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.

  2011cited by this paper
• Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.

  2011cited by this paper
• Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

  2011cited by this paper
• The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

  2010cited by this paper
• Mechanisms of skin fibrosis in systemic sclerosis

  2010cited by this paper
• Future treatments in systemic sclerosis

  2010cited by this paper
• B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

  2009cited by this paper
• Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.

  2009cited by this paper
• A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.

  2009cited by this paper
• An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

  2008cited by this paper
• A retrospective randomly selected cohort study of D‐penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset

  2008cited by this paper
• Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

  2007cited by this paper
• High‐dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma

  2007cited by this paper
• Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.

  2007cited by this paper
• Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease.

  2007cited by this paper
• Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

  2007cited by this paper
• Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab

  2006cited by this paper
• A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

  2006cited by this paper
• A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

  2006cited by this paper
• Cyclophosphamide versus placebo in scleroderma lung disease.

  2006cited by this paper
• B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

  2006cited by this paper
• Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis

  2006cited by this paper
• A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion.

  2005cited by this paper
• Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis.

  2005cited by this paper
• Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement.

  2004cited by this paper
• Fibrosis regression induced by intravenous gammaglobulin treatment

  2003cited by this paper
• The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice.

  2002cited by this paper
• Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

  2002cited by this paper
• Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

  2001cited by this paper
• A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

  2001cited by this paper
• Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.

  2001cited by this paper
• Long-Term Outcomes of Scleroderma Renal Crisis

  2000cited by this paper
• Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma.

  2000cited by this paper
• High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.

  1999cited by this paper
• Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.

  1999cited by this paper
• Intravenous Cyclophosphamide Pulse Therapy for the Treatment of Lung Disease Associated with Scleroderma

  1999cited by this paper
• Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy.

  1999cited by this paper
• Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases.

  1997cited by this paper
• Pilot study of antithymocyte globulin in systemic sclerosis.

  1996cited by this paper
• Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

  1996cited by this paper
• Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis

  1994cited by this paper
• Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

  1991cited by this paper
• Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis.

  1990cited by this paper
• Immunologic aspects of scleroderma

  1989cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Interferon-α and interferon-γ reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture

  1988cited by this paper
• Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture.

  1988cited by this paper
• D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study.

  1987cited by this paper
• D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

  1982cited by this paper
• Penicillamine Therapy in Systemic Sclerosis

  1977cited by this paper

• No citing papers are available for this paper.